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MinireviewChaperoning to the metabolic party: The
emerging therapeutic role of heat-shock proteins
in obesity and type 2 diabetesDarren C. Henstridge 1, Martin Whitham 1, Mark A. Febbraio*ABSTRACT
Background: From their initial, accidental discovery 50 years ago, the highly conserved Heat Shock Proteins (HSPs) continue to exhibit
fundamental roles in the protection of cell integrity. Meanwhile, in the midst of an obesity epidemic, research demonstrates a key involvement of
low grade inﬂammation, and mitochondrial dysfunction amongst other mechanisms, in the pathology of insulin resistance and type 2 diabetes
mellitus (T2DM). In particular, tumor necrosis factor alpha (TNFa), endoplasmic reticulum (ER) and oxidative stress all appear to be associated
with obesity and stimulate inﬂammatory kinases such as c jun amino terminal kinase (JNK), inhibitor of NF-kb kinase (IKK) and protein kinase C
(PKC) which in turn, inhibit insulin signaling. Mitochondrial dysfunction in skeletal muscle has also been proposed to be prominent in the
pathogenesis of T2DM either by reducing the ability to oxidize fatty acids, leading to the accumulation of deleterious lipid species in peripheral
tissues such as skeletal muscle and liver, or by altering the cellular redox state. Since HSPs act as molecular chaperones and demonstrate
crucial protective functions in stressed cells, we and others have postulated that the manipulation of HSP expression in metabolically relevant
tissues represents a therapeutic avenue for obesity-induced insulin resistance.
Scope of Review: This review summarizes the literature from both animal and human studies, that has examined how HSPs, particularly the
inducible HSP, Heat Shock Protein 72 (Hsp72) alters glucose homeostasis and the possible approaches to modulating Hsp72 expression. A
summation of the role of chemical chaperones in metabolic disorders is also included.
Major Conclusions: Targeted manipulation of Hsp72 or use of chemical chaperiones may have clinical utility in treating metabolic disorders
such as insulin resistance and T2DM.
 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Keywords Hsp72; Skeletal muscle; Insulin resistance; Type 2 diabetes; Obesity; Inﬂammation; Oxidative capacity; Mitochondria; Chemical
chaperones1. INTRODUCTION
Heat shock proteins (HSPs) were serendipitously discovered over 50
years ago by the Italian scientist Ferruccio Ritossa. Indeed, the inad-
vertent application of heat shock to drosophila salivary glands (by the
accidental adjustment of incubator settings) and the subsequent
observation of new HSP RNA synthesis remains a striking demonstra-
tion of environmentally induced changes in gene expression [1,2]. A
rather different and no doubt, more complex collective gene response is
occurring consequential of today’s snowballing and problematic envi-
ronment of nutrient excess. Rates of obesity continue to rise and the
understanding of how this leads to metabolic diseases such as type 2
diabetes (T2DM) is improving. However, effective treatments remain
elusive. Given the ubiquity of the highly conserved HSPs, it is perhaps
unsurprising that these chaperone proteins have been implicated in theCellular & Molecular Metabolism Laboratory, Division of Metabolism and Obesity, Baker
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www.molecularmetabolism.comtreatment of insulin resistance and obesity associated T2DM [3,4].
Attracting most attention in this regard is the inducible isoform of
HSP70, Hsp72 (Hspa1a). Experimental models indicate that Hsp72 is
likely to confer protection against disturbed metabolic homeostasis via
multiple modes of action including, but not limited to, reducing
inﬂammation [3,5,6] and improving skeletal muscle oxidation [3,6e8].
Importantly, we [3,8] and others [4,9] have been conducting experi-
ments using a small molecule activator of HSP72 (a hydroxylamine
derivate termed BGP-15). This agent improves insulin sensitivity and
inﬂammation in a genetic mouse model of insulin resistance [3], in-
creases mitochondrial volume and improves metabolic homeostasis in
a rat model of T2DM [8]. This is most promising from a clinical and
translational perspective since BGP-15 has now proceeded to Phase 2b
clinical trials and has previously been used in humans without any side-
effects [4,10]. This review summarizes the accumulating evidence for aIDI Heart & Diabetes Institute, 75 Commercial Rd, Melbourne, Victoria 3004, Australia
ridi.edu.au (M. Whitham), mark.febbraio@bakeridi.edu.au (M.A. Febbraio).
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Minireviewrole of Hsp72 in glucose metabolism and discusses the therapeutic
potential of Hsp72 raising agents in the treatment of conditions asso-
ciated with insulin resistance.
2. HSP EXPRESSION IN INSULIN RESISTANCE AND DIABETES
Arguably the ﬁrst link between HSPs and diabetes was derived from the
observation that in insulin resistant and T2DM patients, HSP expression
was markedly altered. Muscle biopsies taken from patients with T2DM
showed signiﬁcantly lower mRNA levels of Hsp72 than those taken from
non-diabetic controls [11]. Furthermore, data collected in our laboratory
supported this ﬁnding and demonstrated a marked relationship be-
tween Hsp72 mRNA and insulin stimulated glucose uptake during a
hyperinsulemic-euglycemic clamp in T2DM patients [12]. We and
others [13] later demonstrated that skeletal muscle Hsp72 protein
expression reﬂected the same trend as Hsp72 mRNA, supporting the
hypothesis that Hsp72 expression is decreased in T2DM [3]. Early
speculation considered that Hsp72 expression might be affecting insulin
sensitivity through a direct interaction with GLUT4 [11]. However, other
studies found no reduction in GLUT4 gene expression in diabetic pa-
tients versus aged matched controls [12]. In the same study, we directly
measured intramuscular triglyceride (IMTG) content in the muscle bi-
opsy samples derived from T2DM patients and aged matched healthy
controls. IMTG content wasw150% higher in the patient group. Allied
to the ﬁnding of lowered Hsp72 expression in T2DM, these data pro-
vided a rationale for the examination of the role of HSP expression in the
etiology of obesity induced insulin resistance.
3. OBESITY, INFLAMMATION AND INSULIN RESISTANCE
3.1. Low grade inﬂammation
Numerous lines of evidence suggest a link between obesity and
inﬂammation. Prolonged or chronic inﬂammation is associated with a
cluster of metabolic diseases, including T2DM and is referred to as “low
grade” or meta-inﬂammation [14]. While the cascade of molecules
involved in inﬂammation is complex, the pro-inﬂammatory cytokine,
TNFa appears to demonstrate a prominent role in mediating down-
stream transduction cascades that affect insulin signaling. For example,
TNFa is increased in the adipose tissue of obesemice [15]. Moreover, in
loss-of-function experiments in obese mice, null mutations in the gene
encoding TNFa and its receptors resulted in improved insulin sensitivity
[16]. Signiﬁcantly, a multitude of metabolic stressors appear capable of
inducing inﬂammatory signaling pathways. In addition to extracellular
TNFa, stressors originating from within the cell appear inﬂuential. For
example, obesity places overload on the endoplasmic reticulum (ER)
due to an accumulation of misfolded proteins, lipid oversupply and
increased demand on the synthetic machinery [17]. Indeed, in both high
fat diet (HFD) and genetic (ob/ob) models of murine obesity, indicators of
ER stress such as PKR-like kinase (PERK) and eIF2a are signiﬁcantly
phosphorylated in liver extracts from obese versus lean animals [18].
Elevated glucose metabolism can also cause an increase in reactive
oxygen species (ROS) in the mitochondria. Interestingly, gene expres-
sion analysis has suggested a role for ROS in both TNFa and gluco-
corticoid models of insulin resistance [19]. Given that both ER and
oxidative stress are known to induce inﬂammatory signaling cascades
[17,20], these stressors provide additional means by which obesity
might disrupt insulin signaling.
3.2. Inﬂammatory kinases and the disruption of insulin signaling
Since the inﬂammatory serine/threonine kinases, c jun amino terminal
kinase (JNK), inhibitor of NF-kb kinase (IKK), and protein kinase C782 MOLECULAR METABOLISM 3 (2014) 781e793  2014 The Authors. Published by Elsevier GmbH(PKC) disrupt insulin signaling [21e23] blocking their action provides a
possible means for therapeutic intervention to treat insulin resistance.
In particular, the MAPK kinase JNK has emerged as a possible key
regulator of metabolic alterations in insulin sensitivity. Indeed, three
lines of evidence highlight this. Firstly, JNK activity is elevated in both
dietary and genetic models of obesity [24,25] and deletion of two of the
three JNK isoforms, JNK1 [24,26] and JNK2 [26] protects mice from
HFD-induced insulin resistance. Rats fed a high fat “western” diet for
30 days showed higher JNK activity in liver, muscle and hypothalamus,
compared with controls [25]. In addition, JNK phosphorylation is
elevated in liver, muscle and adipose tissues taken from leptin deﬁ-
cient (ob/ob) mice, a commonly used genetic model of murine obesity
[24]. Secondly, JNK is activated by free fatty acids (FFA), TNFa, ER
stress and ROS [17,20,27e29], all of which are known to contribute to
insulin resistance. Finally, JNK serine phosphorylates IRS-1 (ser307)
which disrupts IRS-1 and IR interaction, the proximal step in insulin
signaling [30,31]. Taken together, these ﬁndings provide support for
the notion that JNK1 inhibition might provide a promising therapeutic
avenue for the treatment of T2DM.
4. HSPS AND INFLAMMATION
A key feature of HSPs is their ability to provide cytoprotection. Early
experiments demonstrated that if cells were heat treated to 43 C,
(which increased HSP synthesis) the number of cells surviving a
subsequent insult of heat shock increased [32]. Once it became un-
derstood that HSPs can provide cytoprotection against other stressors,
interest in their therapeutic value increased. For example, preheating
of human leukemic cells led to reduced cell death following a sub-
sequent heat shock, which was associated with an inhibition of JNK1
and p38 activation [33]. That this effect might be mediated by HSPs
was assessed using ectopic over-expression of Hsp72 in the human
PEER cell line. Indeed, overexpression of Hsp72 suppressed the
apoptotic and stress kinase activating effects of heat, osmotic shock,
H2O2 and UV irradiation [33]. Experimental evidence suggests several
potential mechanisms by which HSP72 can downregulate JNK. Ex-
periments utilizing Hsp72 transfected mouse embryonic ﬁbroblasts,
suggested that Hsp72 suppresses the JNK1 signaling pathway through
physical association and prevention of JNK1 phosphorylation by its
upstream kinase SEK1 [34]. In addition, Daviau et al. demonstrated a
role for duel leucine zipper-bearing kinase (DLK) in the mechanism by
which HSP72 can down-regulate JNK. DLK is a member of the mixed
linage kinase family which are known mitogen activated kinase ki-
nases [35]. DLK is a known upstream activator of JNK. These authors
[35] showed in COS-7 cells that HSP72 associates with the HSP co-
chaperone CHIP, a known ubiquitin ligase, which can negatively
regulate DLK expression and activity. These data suggest that the
mechanism by which HSP72 blocks JNK activity is via CHIP mediated
DLK ubiquitination. Finally, others [36] demonstrated a role for the
upstream phosphatase MAP kinase phosphatase-1 (MKP-1) in HSP72
mediated down-regulation of JNK.
5. HSP72 AND THE PREVENTION OF INSULIN RESISTANCE
Meta-inﬂammation appears to disrupt insulin signaling and HSPs
appear to have the potential to inhibit inﬂammatory kinases. Therefore,
there is a strong rationale to investigate the activation and/or upre-
gulation of HSPs as a means to treat insulin resistance. Interestingly,
one preliminary report has suggested that heat therapy in general
might have therapeutic potential. T2DM patients using a hot tub daily
for three weeks exhibited improvements in glycaemia by unknown. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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mechanisms [37]. In order to more comprehensively investigate the
effects of heat therapy and Hsp72 induction on insulin resistance, a
number of experiments were performed [3].
5.1. Heat therapy, JNK1 phosphorylation and insulin sensitivity
Mice were subjected to either heat shock (HT) or sham therapy
(control) whilst consuming a HFD. HT involved raising the core tem-
perature to 41 C for 15 min, once a week, for 16 weeks, which
transiently increased Hsp72 expression in muscle, liver and adipose
tissue. As expected, in response to the HFD, control mice developed
hyperglycaemia, hyperinsulinemia and insulin resistance as indicated
by the homeostatic model assessment of insulin resistance (HOMA-IR).
Furthermore, intraperotineal glucose tolerance tests (IPGTT) revealed
glucose intolerance in these mice. Conversely, mice exposed to HT
were protected against insulin resistance, and this protection was
associated with an attenuation of JNK1 phosphorylation in muscle.
Importantly, this observation has been subsequently conﬁrmed by
others [5,6], demonstrating that heat treatment improves glucose
tolerance and prevents skeletal muscle insulin resistance and JNK1
phosphorylation in high fat fed rodents [6]. Morino and colleagues
demonstrated that a combination of mild electrical stimulation (MET)
and HT in high fat-fed and db/db mice for 10 min applied twice a week
for 12 weeks decreased fasting blood glucose and insulin levels and
improved insulin sensitivity. These observations were associated with
decreased fat mass and a decrease in the phosphorylation of JNK1 [5].
Interestingly this MET protocol also protects pancreatic b-cells from
high glucose and ER and oxidative stress [38]. MET increases HSP72 in
the pancreas of db/db mice. When these mice were challenged with a
glucose load, an increase in insulin secretion was observed. WhenFigure 1: Impact of whole body heat shock treatment (HT) or HT plus mild electric stimu
insulin resistance or T2DM. HT typically involves acutely warming rodents to 41e42 C acu
adipose tissue, the heart and brain, these organs have not been investigated thoroughly in
brown adipose tissue and the gut with such a treatment protocol. The effects of HT on the
shock response involves the attenuation of inﬂammatory markers (JNK, IKK-b and NF-kB)
restoration of impaired vasodilation in vessels (see Refs. [3,5,6,38,96]).
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pancreatic duodenal homeobox-1 (PDX-1), GLUT2, and insulin receptor
substrate-2 were upregulated in the islets of MET-treated mice,
whereas the phosphorylation of JNK, nuclear translocation of forkhead
box class O-1 (FOXO1), and nuclear factor-kB p65 were reduced [38].
Apoptotic signals, ER stress, and oxidative stress markers were also
attenuated [38]. Together, a summary of the effects of HT and MET are
displayed in Figure 1.
5.2. Genetic over-expression of Hsp72 and HFD induced insulin
resistance
While heat treatment showed improvements in insulin signaling in a
HFD model of insulin resistance, the non-speciﬁc nature of heat as a
global stressor precludes ﬁrm conclusions on the involvement of HSPs.
Therefore, transgenic mice, overexpressing Hsp72 in skeletal muscle
(Hsp72þ/þ) were placed on a chow or HFD and compared with wild
type (WT) controls to determine the speciﬁc effects of Hsp72 expres-
sion on diet induced insulin resistance. In keeping with the heat therapy
data, the development of hyperglycaemia, hyperinsulinemia, insulin
resistance and glucose intolerance was prevented in Hsp72þ/þ mice
as opposed to the WT controls. Given the role of inﬂammatory kinases
in the disruption of insulin signaling, JNK1 and IKK phosphorylation was
assessed in Hsp72þ/þ and WT mice. While neither the diet nor
treatment altered IKKab serine phosphorylation, JNK (Thr183/Tyr185)
phosphorylation was increased in WT mice following the HFD. Again, in
keeping with the hypothesis, JNK1 phosphorylation was completely
prevented in Hsp72þ/þ mice. Furthermore, when stimulated with
insulin, AKT phosphorylation was elevated in Hsp72þ/þ but not WT
mice following the HFD (see Figure 2). These data indicated, therefore,lation (MET) on various organs relating to whole body metabolism in mouse models of
tely once per week. While it is known the Hsp72 is elevated in response to heat in white
regards to metabolism. We are not aware of reports demonstrating increases in Hsp72
liver, pancreas, skeletal muscle and the vasculature have been well described. The heat
in multiple organs, improvements in insulin stimulated signaling in muscle and liver and
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). 783
Figure 2: Comparison of mouse models where Hsp72 has been transgenically overexpressed or knocked out focusing speciﬁcally on the skeletal muscle. In many respects the
opposite phenotype is observed between the two models. While Hsp72 transgenic mice are protected against obesity-induced insulin resistance, Hsp72 knockout mice are heavier
and insulin resistant on a normal chow diet at 7 months of age. While indicators of oxidative capacity such as endurance capacity, b-HAD activity, mitochondria number and
skeletal muscle lipid oxidation are increased in the transgenics, many of these parameters are decreased or impaired in the knock-outs. Further, while overexpression of Hsp72
resulted in a decrease in HFD intramusclular TAG and DAG lipid accumulation, the lipid levels of this class of lipids were increased in the Hsp72 knock-outs (see Refs. [3,8,83]).
Minireviewthat overexpression of Hsp72 inhibited fatty acid disrupted
insulin signaling, through the inhibition of the JNK1 pathway of
inﬂammation.
5.3. Pharmacological induction of Hsp72 with BGP-15
Given the signiﬁcance of the presented ﬁndings, it is important from a
therapeutic point of view, to determine ways in which Hsp72 can be
induced. In this regard, hydroxylamine derivatives are thought to
stimulate HSP expression by prolonging activation of HSF1 [39] and
alteration of membrane lipid microdomains [40]. Indeed, recent studies
demonstrated that the hydroxylamine derivative, BGP-15 was able to
remodel cholesterol-enriched lipid platforms and that enhanced
membrane ﬂuidization was necessary for transmembrane signaling to
proceed upon BGP-15 treatment [41]. The therapeutic utility of BGP-15
has been determined in a well known model of obesity and diabetes,
the ob/ob mouse. Mice treated with BGP-15 by oral gavage demon-
strated a signiﬁcant increase in intramuscular Hsp72 compared with
mice receiving control treatment (saline). In support of previous ﬁnd-
ings, the increased Hsp72 expression was associated with decreased
activation of JNK1 phosphorylation. Furthermore, BGP-15 treated mice
presented with improved fasting glucose and insulin concentrations
than control mice and a hyperinsulinemic euglycaemic clamp revealed
markedly improved glucose disposal rate in the pharmacologically
treated mice. These data demonstrate that BGP-15 is able to induce
heightened expression of Hsp72 in genetic models of obesity and that
this increased protection is associated with improved glycaemia and
insulin signaling via suppression of JNK1 activation. Importantly BGP-
15 has been demonstrated to be effective in humans. In a cohort of 47
insulin resistant non-diabetic patients BGP-15 administered orally for
28 days was shown to improve whole body glucose disposal during a
hyperinsulinemic euglycaemic clamp. No adverse drug effects were
observed during treatment and the BGP-15 was reported as safe and784 MOLECULAR METABOLISM 3 (2014) 781e793  2014 The Authors. Published by Elsevier GmbHwell tolerated [4]. Recently, results indicate that BGP-15 inhibits
multiple metabolic side effects of atypical antipsychotics, and this
effect is likely to be related to its HSP co-inducing ability [9]. By way of
further support for the pharmacological manipulation of Hsp72
expression, Acylic Polyisoprenoid Derivative Geranylgeranylacetone
(GGA), known primarily as an anti-ulcer drug, was found to be pro-
tective against visceral adiposity and insulin resistance in high fat fed
mice [42]. Four weeks of GGA administration increased Hsp72 in the
liver as this treatment resulted in improved insulin sensitivity and
glucose homeostasis upon glucose challenge. In line with the ﬁndings
using BGP-15, activation of JNK1 was attenuated and insulin signaling
was improved in the livers of high fat fed mice. These data suggest that
induction of liver Hsp72 by BGP-15 or GGA is beneﬁcial in protecting
against a high fat diet in a rodent model. Encouragingly these ﬁndings
were replicated in spontaneously diabetic primates, demonstrating an
85% improvement in glucose tolerance and a 42% lower and improved
HOMA index for insulin resistance [43].
5.4. Are the protective effects of activation of Hsp72 in metabolic
disease dependent upon blocking JNK activation?
While numerous data support the proposed role of JNK phosphoryla-
tion in the development of diet induced insulin resistance, contradictory
data also exist. For example, electroporation of a constitutively active
construct of JNK (CaJNK) decreased glucose clearance into the tibialis
anterior muscle, but expression of a wildtype (WT-JNK) construct had
no impact [44]. In a similar study, expression of constitutively active
construct of JNK in skeletal muscle of mice had no effect on energy
homeostasis and glucose metabolism [45]. Furthermore, since our
original experimental interventions [3], we have observed no change in
JNK phosphorylation in response to a shorter 10 week HFD, comprised
of a lower percentage of fat, despite the development of insulin
resistance [8]. Since BGP-15 administration improved insulin. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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sensitivity, investigation of inﬂammatory independent, alternative
mechanisms by which Hsp72 impacts on insulin action were
warranted.
5.5. Hsp72 and potential tissue crosstalk
While high level Hsp72 overexpression in the skeletal muscle of the
transgenic mice provided numerous beneﬁts to the muscle itself,
analysis of other tissues from these mice suggests that they also
beneﬁted. An increase in insulin-stimulated glucose clearance into
both white and brown adipose tissue was observed, even though
Hsp72 was not overexpressed in these peripheral tissues [8]. Inter-
estingly, further analysis of the white adipose tissue also revealed
increased rates of lipolysis and maximal activities of the oxidative
enzymes CS and b-hydroxyacyl CoA dehydrogenase (b-HAD) [8].
Recent observations suggest a similar phenomenon in the liver. High
level Hsp72 expression in the skeletal muscle was associated with
increased CS and b-HAD activity in the liver, while lipidomic screening
via mass spectrometry revealed that although WT mice develop he-
patic steatosis with high fat feeding as evidenced by signiﬁcantly
elevated Triacylglycerols (TAGs) and Diacylglycerols (DAGs), Hsp72þ/
þ are completely refractory to this occurring (Henstridge and col-
leagues, unpublished observations). Thus, the transgenic over-
expressing of Hsp72, resulting in a ramping up of oxidative capacity or
blocking of inﬂammation may exert a protective effect on other pe-
ripheral tissues (possible mechanisms depicted in Figure 3). In many
respects, this is similar in nature to exercise training improving hepatic
steatosis in humans or rodents independently of any weight loss [46e
48], although it should be noted that exercise training can decrease fatFigure 3: Schematic representation of the effects of skeletal muscle Hsp72 over-
expression on other insulin sensitive peripheral tissues. Alterations include an increase
rate of glucose clearance into both BAT and WAT, an elevation in oxidative enzymes in
WAT and liver, increased lipolysis in WAT and a decrease in hepatic steatosis (decrease
in the TAG and DAG lipid species). These observations could potentially be explained by
the ramping up of oxidative capacity in the myocytes acting in a protective manner.
Increases in oxidative capacity in the muscle may lead to an increased siphoning of fatty
acids through this tissue, shielding the other organs from their deleterious effects.
Another theory could be that a currently unknown secreted factor (myokine) is released
from the skeletal muscle bed that then exerts effects on these other organs (see Ref. [8]).
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change in body mass but improved body composition [49]. While the
skeletal muscle is the organ manipulated (contraction with exercise,
Hsp72 overexpression in Hsp72þ/þ) another independent organ
beneﬁts. Given these ﬁndings it is an interesting notion to consider
whether targeting the skeletal muscle is a viable option to treat fatty
liver disease. Alternatively, the possibility exists that Hsp72 may be
eliciting some type of tissue cross talk, whereby a secreted substance
from the muscle, termed a “myokine” (for review see Ref. [50]), may
then act on other tissues. Hsp72 is secreted from cells independently
of the common secretory pathway and instead via an exosome
dependent mechanism [51]. There is growing evidence linking the
expression of Hsp to changes in the lipid composition and architecture
of plasma membranes [41], and it has been suggested that Hsps
complex with caveolin to be released from plasma membranes via lipid
rafts (for review see Ref. [52]). Recently Uyy et al. [53], demonstrated
that detergent resistant membranes isolated from mice fed a high fat
diet contained Hsps and caveolin-1 which positively correlated with
Hsp secretion into the plasma. Together, these data suggest that Hsps
are secreted from cells in a regulatory manner and give rise the
possibility that Hsp72 may yet be another myokine capable of tissue
cross talk. Indeed, Hsp72 is known to be released into the systemic
circulation upon physical activity but it is unlikely derived from skeletal
muscle (reviewed in Ref. [54]). However, it is unknown whether high
level overexpression, such as that observed in the Hsp72þ/þ mice
can elicit such an effect.
6. OBESITY, MITOCHONDRIAL FUNCTION AND INSULIN
RESISTANCE
6.1. Mitochondrial dysfunction in obesity induced insulin
resistance: cause, consequence or other?
A great deal of research over the past few decades has investigated
whether obesity and insulin resistance are linked to a defect in the
energy producing organelle, the mitochondria. While it is still contro-
versial as to exactly how mitochondrial stress impacts insulin action in
muscle, whether mitochondrial dysfunction is a cause or consequence
of insulin resistance, or whether mitochondrial dysfunction exists at all
in parallel with insulin resistance (these issues reviewed in Refs. [55e
61]), there is the distinct possibility of harnessing the function of the
mitochondria to treat obesity and insulin resistance. Some of the lines
of evidence suggesting insulin resistance is associated with defective
oxidative metabolism in skeletal muscle are now described.
6.1.1. Mitochondrial dysfunction in metabolically impaired humans
Peroxisome proliferator-activated receptor-g coactivator (PGC-1a)
has become known as the master regulator of mitochondrial
biogenesis/oxidative metabolism due to its role as a transcription
factor in regulating mitochondria biogenesis. Increased PGC-1a leads
to up-regulation of target genes such as nuclear respiratory factor 1
(Nrf-1) which can, in turn, stimulate the expression of OXPHOS genes
and mitochondrial transcription factor A (Tfam), a mitochondrial
matrix protein essential for transcription of mitochondrial DNA [62]. A
reduction in the expression of genes encoded by PGC-1a is observed
in skeletal muscle of patients with T2DM [63,64] and healthy in-
dividuals with a family history of diabetes [64]. Skeletal muscle
mitochondrial function may play a role, therefore, in the pathogenesis
of T2DM. Skeletal muscle of insulin-resistant offspring of patients
with T2DM is associated with dysregulated fatty acid metabolism,
possibly due to an inherited defect in mitochondrial oxidative phos-
phorylation [65]. Moreover, mitochondrial oxidative activity in healthy,access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). 785
Minireviewlean, elderly volunteers with severe muscle insulin resistance is
reduced compared with BMI and activity matched younger control
subjects and this is associated with increased intramyocellular and
hepatic lipid content [66]. This is suggestive of a predisposition to
store lipid, leading to insulin resistance through mitochondrial
dysfunction in the elderly [66].
6.1.2. Evidence from animal models and patients with
mitochondrial mutations
Animal models suggest increasing oxidative metabolism may be
beneﬁcial in the setting of insulin resistance. Activation of key pro-
teins and/or pathways involving AMP-activated protein kinase (AMPK)
[67], Peroxisome proliferator-activated receptor delta (PPARd) [68],
sirtuin 1 (SIRT)1 [69] and carnitine palmitoyltransferase-1 (CPT1) [70],
increase fatty acid oxidation (FAO). This has the downstream effect of
decreasing lipid esteriﬁcation and, in doing so, ameliorates insulin
resistance. Such interventions would counteract any deﬁciencies in
mitochondrial oxidative function that may be present in the diseased
state. A caveat to such thought is the fact that high fat feeding in
rodents which causes insulin resistance has been known to increase,
rather than impair, the ability of the muscle bed to oxidize lipids [71].
However, it should be noted that this increase is insufﬁcient to ac-
count for the increase in lipid uptake and as a consequence lipid
esteriﬁcation increases, despite the increase in lipid oxidation [70].
Metabolic studies on patients with mitochondrial myopathies caused
by genetic mutation provide a link between disruption to the mito-
chondria and glucose homeostasis and insulin action. A genetic point
mutation affecting position 3243 in the tRNA leucine mitochondrial
gene results in decreased insulin sensitivity in patients with this
mutation [72] and maternally transmitted T2DM [73]. In addition,
patients with one of the more common types of mitochondrial dis-
eases, Chronic Progressive External Ophthalmoplegia, have impaired
glucose tolerance [74].
6.1.3. Mitochondrial shape, ROS and supply and demand
Another important consideration is the architecture of the mitochon-
dria. If mitochondria lose their shape, their dynamics and health can
change. This can result in alterations to mitophagy (the autophagic
breakdown of mitochondria). Either a decrease or increase in rates of
mitophagy may impact a cell negatively. Indeed, long term con-
sumption of a HFD in mice leads to changes in the appearance of
mitochondria in that they become swollen [75]. The generation of ROS,
which can be associated with dysfunctional mitochondria, also leads to
insulin resistance [19,76]. ROS production and ROS signaling is,
therefore, another manner in which mitochondria function/dysfunction
may be associated with nutrient stress in the obese or insulin resistant
state. Indeed, it has been demonstrated that in skeletal muscle of both
rodents and humans, a HFD increases the H2O2-emitting potential of
mitochondria which, in turn, shifts the cellular redox environment to a
more oxidized state, thereby decreasing the redox-buffering capacity.
Intriguingly, this occurs without any change in mitochondrial respira-
tory function [77]. This line of thinking suggests skeletal muscle insulin
resistance is related to redox pressures that are placed on the respi-
ratory system when energy supply outpaces energy demand [55].
Although controversy will continue to persist as to the exact nature of
the mitochondria’s involvement in the obese and/or insulin resistant
state, targeting of the mitochondria for therapeutics will need to take
into consideration the ability of the mitochondria to oxidize and,
therefore, remove lipid from the cell, the continual maintenance of
normal mitochondrial architecture and the nutrient supply and demand
equation.786 MOLECULAR METABOLISM 3 (2014) 781e793  2014 The Authors. Published by Elsevier GmbH7. HSP72, MITOCHONDRIA AND INSULIN RESISTANCE
7.1. Associations between Hsp72 and mitochondrial biology
Since mitochondrial dysfunction is associated with insulin resistance
and Hsp72 is known to protect cardiac muscle against mitochondrial
damage caused by ischemia reperfusion injury [78], that Hsp72 might
alter mitochondrial function during nutrient excess became of interest.
Signiﬁcantly, heat therapy increases both mitochondrial enzyme ac-
tivity and exercise endurance capacity in rats [79] along with mito-
chondrial biogenesis in C2C12 myocytes [7] and oxygen consumption
in L6 muscle cells [6]. From a correlative perspective Hsp72, has been
linked to oxidative potential due to its abundance in certain skeletal
muscles. Indeed, Hsp72 expression is correlated with skeletal muscle
oxidative capacity with more oxidative ﬁber types expressing higher
levels of Hsp72 [80]. Hsp72 is expressed at higher levels in the more
slow-twitch oxidative soleus skeletal muscle than the epitrochlearis
muscle which is more of a mixed ﬁber muscle [81]. Similar to the
ﬁndings with Hsp72 expression, phosphorylation of Hsp25 was also
signiﬁcantly higher in the more oxidative soleus muscle [81].
Furthermore, a signiﬁcant positive correlation between the mRNA
expression of Hsp72 and mitochondrial enzyme activity has been
observed in human skeletal muscle [12]. It is important to note the
observation of smaller fat pads in HSP72þ/þ mice compared with WT
mice, even though the daily food intake was the same when comparing
strains.
7.2. Genetic over-expression of Hsp72 and mitochondria
The oxidative capacity in skeletal muscle of WT and HSP72þ/þ mice
was examined by measuring the maximal activities of two important
mitochondrial enzymes, citrate synthase (CS) and b-hydroxyacyl-CoA-
dehydrogenase (b-HAD). Interestingly, the maximal activities of these
enzymes was higher in HSP72þ/þ compared with WT mice [3]. These
data suggested that Hsp72 increases the fatty acid oxidative capacity
in skeletal muscle, which may account for the protection against in-
creases in body weight and resultant insulin resistance. By way of a
more thorough investigation, we recently examined transgenic Hsp72
(HSP72þ/þ) and control (WT) mice fed a regular chow (chow) or high
fat diet (45%) (HFD) for 10 weeks. The duration and composition of the
HFD was chosen speciﬁcally so that JNK was not activated in skeletal
muscle and therefore any changes observed were independent of JNK.
While the HFD markedly increased body weight, epididymal fat pad
mass and intramuscular lipid accumulation and induced insulin
resistance in WT, no such effects were seen in Hsp72þ/þ mice.
Despite equivalent food intake, whole body oxygen consumption, fatty
acid oxidation and oxidative enzyme activity in skeletal muscle were
increased in Hsp72þ/þ irrespective of diet. Furthermore, when
subjected to an endurance exercise treadmill test, Hsp72þ/þ mice
displayed a 2-fold increase in running capacity relative to WT mice.
Consistent with this oxidative phenotype, HSP72Tg mice exhibited a
50% increase in mitochondria and a signiﬁcant increase in Tfam mRNA
expression, a gene important for stimulation of mitochondrial
biogenesis [8]. To further characterize these tissues we measured the
activity of AMP-activated protein kinase (AMPK), a sensor of cellular
energy status, critical for enhancing fuel utilization and metabolism.
Indeed, AMPK phosphorylation (at the Thr172 site) and activity levels
were enhanced in the muscles from HSP72þ/þ relative to WT mice,
via mechanisms not yet elucidated. Another important fuel-sensing
molecule is the NADþ-dependent deacetylase Sirtuin 1 (SIRT1).
SIRT1 is an important regulator of oxidative metabolism and a detailed
review of its metabolic actions in various mouse models has recently
been described in Ref. [82]. The protein expression of SIRT1 was also. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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signiﬁcantly increased in the skeletal muscle of HSP72þ/þ. Whether
SIRT1 is the mechanism behind the increased oxidative capacity with
HSP72 overexpression is yet to be fully elucidated. A summary of the
Hsp72þ/þ phenotype is illustrated in Figure 2.
7.3. Genetic deletion of Hsp72 and mitochondria
In contrast, Hsp72 knockout (Hsp72/) (global null mutation of
Hspa1a/Hspa1b genes) mice develop obesity and insulin resistance
and display marked accumulation of lipid in skeletal muscle (see
Figure 2 for summary). In addition, oxygen uptake and fatty acid
oxidation rates were lower, while fatty acid esteriﬁcation rates higher in
primary myocytes obtained from HSP72/ mice compared with WT
[83] The hypothesis that Hsp72 stimulates fat oxidation with a
consequent reduction in fat storage and adiposity gained further
support in a clinical study, which observed lower expression of Hsp72
protein in human skeletal muscle associated with increased adiposity
and decreased insulin sensitivity in healthy individuals [84]
7.4. Other HSPs?
While this review has largely focused on Hsp72, it is of note that other
HSP families may also be fundamental in mitochondrial homeostasis
and maintenance of insulin sensitivity. For example, Kleinridders and
colleagues [85] used a murine model of T2DM, and demonstrated
hypothalamic insulin resistance and mitochondrial dysfunction due to
downregulation of the mitochondrial chaperone HSP60. HSP60
reduction in obese, diabetic mice was due to a disruption of leptin
signaling and was restored by leptin treatment. In vitro, knockdown of
Hsp60 in a mouse hypothalamic cell line mimicked the mitochondrial
dysfunction observed in diabetic mice [85]. The small HSP, HSP25 has
also been implicated in the etiology of metabolic disease. Consistent
with the pre-clinical data for HSP72, HSP25 protein expression is also
reduced in the skeletal muscle of aged, insulin resistance rats [81].
Adipose tissue biopsies comparing lean versus obese patients deter-
mined that the DNAJB3 cochaperone (a member of the HSP40 family)
mRNA and protein levels were decreased in the obese patients [86].
Interestingly DNAJB levels positively correlated with maximum oxygen
consumption in these patients and exercise training restored the
expression of DNAJB3 in obese subjects with a concomitant decrease
of phosphorylated JNK [86]. Somewhat paradoxically, work from the
same group, using a similar model demonstrated increased expression
of HSP60, HSP90 and GRP-94 in obese adipose tissue [87].
7.5. Small molecule activators of Hsp72 and mitochondrial
physiology
Since we have shown that Hsp72 expression can be manipulated
pharmacologically, what evidence is there that activators of HSP
expression can alter mitochondrial physiology? A recent study inves-
tigating diabetic peripheral neuropathy (DPN) in both type 1 and type 2
diabetes mouse models demonstrated that the small molecule Hsp72
modulating compound KU-32 improved mitochondrial bioenergetics
and decreased DPN [88]. KU-32 is a novel, novobiocin-based Hsp90
inhibitor. Upon exposure to Hsp90 inhibitors, heat shock factor 1
dissociates from Hsp90, translocates to the nucleus, and upregulates a
heat shock response that promotes synthesis of chaperones, such as
Hsp72 [88]. Importantly from a mechanistic stand point, the improved
mitochondrial function with KU-32 was dependent on Hsp70 as when
the drug was administered to Hsp70/mice it was no longer effective
[88]. There is evidence to suggest that BGP-15 may also effective at
the mitochondrial level. Studies investigating BGP-15 treatment on
mitochondrial density in skeletal muscles from Goto-Kakizaki (GK) rats,
a non-obese Wistar substrain which develops T2DM early in life [89],MOLECULAR METABOLISM 3 (2014) 781e793  2014 The Authors. Published by Elsevier GmbH. This is an open
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associated with improved glucose infusion rates during a clamp [8].
Interestingly, while BGP-15 is an Hsp72 co-activator, it may be a multi-
target agent. Studies investigating the cardioprotective effect of BGP-15
have demonstrated it to be a poly(ADP-ribose)polymerase (PARP-1)
enzyme inhibitor. This inhibition of PARP-1 activation leads to protection of
the mitochondria from oxidative damage under the condition of ischemia-
reperfusion in a rat heart model [90,91] and like the overexpression of
Hsp72, leads to a reduction in the phosphorylation of JNK [92]. Recently, a
clear role of PARP-1 inhibition in metabolic health was described by
Auwerx and colleagues when they demonstrated that PARP inhibition
improves ﬁtness and mitochondrial function in skeletal muscle [93]. In
experiments involving worms, mice and humans, the investigators were
able to establish that PARP inhibition can offset genetic and acquired
defective mitochondrial function. In summation of this work, PARP-1
expression negatively correlated with energy expenditure in a heteroge-
neous mouse population (BXDmouse genetic population). Inhibiting PARP
pharmacologically was able to enhance energy expenditure, SIRT1 ac-
tivity, Tfam expression, CS activity, endurance exercise capacity and
mitochondrial function while improving oxidative capacity in models of
reduced mitochondrial function [93]. The contribution of SIRT1 in medi-
ating these effects were studied by repeating these experiments in
muscle-speciﬁc SIRT1 deﬁcient mice, where PARP inhibition no longer
enhanced endurance capacity, respiratory capacity or CS activity [93]. As
ablation of PARP-1 increases NADþ availability [94] and NADþ plays an
important role in controlling metabolic health via a SIRT1 dependent
mechanism [95], it seems likely that SIRT1 is a key component of this
attractive potential therapeutic pathway. Intriguingly, heat treatment,
which increases Hsp72 also increases SIRT1 expression in muscle cells
[7] and in the vasculature of rats [96]. Furthermore, it is also increased in
skeletal muscle of HSP72þ/þmice [8] suggesting similar pathways may
be involved. Investigation of the effect of compounds such as BGP-15 and
GGA onSIRT1 pathways are yet to be carried out but are clearly warranted.
7.6. Hsp72 and mitophagy
Since HSPs most prominent annotation is cell protection and insulin
resistance and has been associated with mitochondrial dysfunction, we
have considered the possible inﬂuence of Hsp72 on the fundamental
preservation of this organelle during nutrient oversupply. Indeed, by
manipulating HSF-1, the central regulator of Hsp72, Dokladny et al. [97]
recently demonstrated a primary role of Hsp72 in autophagy, the vital
process of digestion of unnecessary or dysfunctional cellular compo-
nents. Signiﬁcantly, in HSP72 KO mice (which lack hspa1a and hspa1b
genes), loss of Hsp72 causes enlarged and damaged mitochondria
which is paralleled by skeletal muscle insulin resistance and increased
adiposity [83]. These series of studies were able to show that Hsp72 is a
critical regulator of stress-inducedmitochondrial turnover as Parkin, (an
E3 ubiquitin ligase known to regulate mitophagy), was unable to
ubiquitinate and regulate its own protein expression or the protein level
of its central target mitofusin 2 (Mfn2) in the absence of Hsp72. Further,
it was demonstrated that Hsp72 rapidly translocates to damaged
mitochondria prior to Parkin recruitment and immunoprecipitates with
both Parkin and Mfn2 only after speciﬁc mitochondrial insult. This data
implicates Hsp72 as a mitochondrial stress sensor which is critical for
the maintenance of mitochondrial and metabolic homeostasis [83]. The
importance of this functional interaction between Hsp72 and Parkin was
highlighted by publications from two other groups outlining similar
ﬁndings from large screening based discovery platform studies [98,99].
Speciﬁc, detailed future studies are warranted to further study the
parkin/Hsp72 interaction and its role in not only mitochondrial health but
insulin sensitivity.access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). 787
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8.1. Vascular defects, complications and insulin resistance
In what is probably an under-examined area of the ﬁeld, it has become
increasingly recognized that vascular defects (especially in the
microvasculature) can contribute to insulin resistance in muscle (and
perhaps other tissues such as adipose tissue and the liver). The un-
derlying consequence of any insulin resistance induced vascular defect
is impaired delivery of insulin and/or glucose to the skeletal muscle
bed, which leads to insulin resistance [100]. Insulin plays an important
role in the regulation of dilation of blood vessels via stimulation of nitric
oxide (NO) [101]. As NO release is a critical component of normal
vascular biology, any impact on this process can have consequences
on whole body hemodynamic function. Indeed, essential hypertension
is associated with lower NO levels [102], and decreased NO release
has been observed in the setting of atherosclerosis [103]. Impairments
in the vasculature can, therefore, be both a contributing factor to the
development of insulin resistance and contribute to the progression of
vessel disease in metabolic disease. These are important consider-
ations given the close association between metabolic health and
cardiovascular complications.
8.2. Hsp72 and insulin-resistance induced endothelial dysfunction
A recent study has now linked Hsp72 to the vascular complications
associated with high fat feeding induced insulin resistance [96]
(Figure 1). Karpe and Tikoo made the observation that Hsp72
expression is reduced in the aortas of HFD-fed rats and that a heat
shock treatment (HT) regime could restore the Hsp72 expression back
to normal levels [96]. The renineangiotensin system (RAS) is the
predominant hormone system that regulates blood pressure and
importantly, from a functional perspective, while insulin resistance
appears to impair the angiotensin (ANG) ANG1-7 induced vasodilator
response, the induction of Hsp72 attenuates this impairment [96].
ANG-(1e7) opposes the actions of ANG II (a potent vaso-constrictor)
and therefore pushes the system towards a state of vasodilation.
The improvement in ANG(1e7) induced vasodilator response coincided
with multiple changes in signaling events. While HFD fed rats showed
attenuated endothelial nitric oxide synthase (eNOS) phosphorylation,
AMPK phosphorylation and SIRT1 expression, the HT prevented the
attenuation in these signaling pathways [96]. Further, implicating
eNOS and SIRT1 in this pathway, inhibition of these proteins prevented
the beneﬁts of HT. Mechanistically, this is quite similar to the ﬁndings
from the Hsp72þ/þ mice whereby SIRT1 protein levels, AMPK
phosphorylation and AMPK activity levels were increased in the skel-
etal muscle of the transgenic mice [8].
The induction of Hsp72 protein could, therefore, also be an approach to
prevent insulin-resistance-induced vascular complications. Decipher-
ing exactly the percentage contribution of oral agents such as BGP-15,
GGA or new generation Hsp72-raising agents on improving whole body
metabolism via direct impact on the skeletal muscle or improvements
in the vasculature would be a difﬁcult task, but an interesting line of
scientiﬁc enquiry. From a patient’s perspective, the precise mode of
action it is probably inconsequential as long as they have access to a
safe and effective treatment.
9. HSP72 AND AGING
While many physiological factors contribute to aging, a decline in
mitochondrial function, quality or content has been demonstrated to
play a key role in the aging process and is implicated in a number of
age-related disorders such as, but not limited to obesity, insulin788 MOLECULAR METABOLISM 3 (2014) 781e793  2014 The Authors. Published by Elsevier GmbHresistance, T2DM, cancer, cardiovascular disease and neurodegen-
erative diseases such as Alzheimer’s disease and Parkinson’s disease.
It has been shown that many tissues including skeletal muscle from
aged individuals have lower respiratory function compared with those
from younger individuals [104e106]. Hsp72 expression (along with
phosphorylation of Hsp25) is reduced in both slow-twitch oxidative
skeletal muscle (soleus) and mixed muscle (epitrochlearis) with
increasing age (3-month-old versus 24-month-old rats) [81]. This
decrease in HSP expression corresponded to a decline in 2-
deoxyglucose uptake and insulin signaling in the muscle with age
[81]. As summarized in this review, Hsp72 plays an important role in
skeletal muscle mitochondrial dynamics and, as such, Hsp72 elevation
may assist in maintenance of mitochondrial function in the face of
functional decline with aging. Indeed, studies in both mammals and
birds have revealed that Hsp70 levels in different tissues from various
organs are positively correlated with lifespan [107]. Highlighting the
Hsp72/aging interaction, a recent longitudinal study in non-human
primates demonstrated that low baseline levels of skeletal muscle
Hsp70 was a marker for developing insulin resistance within the four
year study period, while a positive change in skeletal muscle Hsp70
levels was beneﬁcial in protecting deterioration of insulin sensitivity
[108]. If it can be demonstrated that Hsp72 induction is efﬁcacious in
improving various aspects and types of mitochondrial dysfunction,
targeted manipulation of Hsp72 with activating compounds may have
clinical utility in a number of mitochondrial related disease states
including but not limited to human aging and T2DM.
10. CHEMICAL CHAPERONES
10.1. Protein folding and chaperones
Protein misfolding and aggregation are associated with a number of
human diseases. Misfolded proteins can aggregate and impair signal
transduction pathways or cause cell toxicity. While mutations are a
common cause of misfolded proteins, they are not an absolute
requirement for misfolding to occur. Protein folding involves the
participation of accessory components (molecular chaperones) of
which Hsp72 is one such component. The ability of chaperones to
discriminate between properly folded and misfolded proteins has led to
the thought process that chaperones provide the cell with a type of
quality control system, recognizing, retaining and targeting misfolded
proteins for degradation [109]. Molecular chaperones participate,
therefore, in both the folding process of proteins and as an important
component in targeting misfolded proteins to degradation.
Chemical chaperones (or pharmaceutical chaperones) are small mol-
ecules that stabilize the folding of proteins, provide improvements to
protein folding and buffer abnormal protein aggregation. Like the
protein molecular chaperones, the different chemical chaperones in-
ﬂuence the rate of ﬁdelity of the folding reaction, probably by stabilizing
the properly folded form of the polypeptide [109]. Given the funda-
mental parallels in function between molecular protein chaperones like
Hsp72 and their pharmaceutical equivalents, it is prudent to consider
the therapeutic potential of these compounds.
10.2. Endogenous chaperones and insulin resistance
As mentioned earlier, ER stress has been implicated in obesity-induced
insulin resistance and the impact of an increase in ER stress has
largely been linked to the activation or hyperactivation of JNK. Some of
the initial evidence linking chaperones and insulin resistance comes
from studies which genetically altered the inducible endogenous ER
chaperone protein, oxygen regulated protein 150 (ORP150). When this
local ER chaperone is decreased, the resultant phenotype is insulin. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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resistance; while conversely, overexpression of ORP150 in mice that
are obese improves insulin tolerance [110]. Furthermore, ORP150
overexpression, speciﬁcally in the liver, markedly reduces insulin
resistance and ameliorates glucose intolerance in obese diabetic mice
[111]. These data provided evidence, therefore, that alterations in local
chaperone expression can impact on whole body insulin sensitivity.
10.3. Chemical chaperones and insulin resistance
Importantly, small molecule chemical chaperones are effective in
alleviating obesity-induced ER stress and ameliorating insulin resis-
tance and diabetes in mice [18] Ozcan and colleagues tested two types
of chemical chaperones, 4-phenyl butyric acid (PBA or 4-PBA), which
is a low molecular weight compound and taurine-conjugated urso-
deoxycholic acid (TUDCA), an endogenous bile acid derivative. Both of
these treatments had been demonstrated to modulate ER function and
in this study, demonstrated strong capacity to alleviate ER stress in
both cultured cells and in in vivo animal studies [18]. Administration of
these compounds orally to a genetic model of obesity and insulin
resistance (the ob/ob mouse) resulted in normalization of blood
glucose levels and improvements in insulin sensitivity within a week of
treatment [18]. Analysis of the organs from these mice (predominantly
liver and adipose tissue) revealed that the chemical chaperone
administration resulted in near complete reversal of the obesity-
induced JNK activation and recovered the defective insulin receptor
signaling associated with the obese condition [18]. The effect on in-
sulin signaling was further characterized by Zhou and colleagues when
they demonstrated that reductions in ER-stress by TUDCA, rescued
obesity-induced insulin receptor (IR) down-regulation and insulin
resistance both in in vivo and in vitro settings [112]. To complement
these ﬁndings, a more recent study investigating proteasomal
dysfunction as a mediator of obesity-induced ER stress and insulin
resistance in the liver demonstrated that PBA administration almost
completely alleviated proteasome dysfunction mediated insulin resis-
tance [113].
While chemical chaperone enhancement has been quite thoroughly
investigated in the liver and adipose tissue, not as much attention has
been paid to the skeletal muscle. ER stress and the activation of the
unfolded protein response (UPR) to maintain ER homeostasis under
such conditions has been reported to occur in skeletal muscle
[114,115]. However, dampening of ER stress signaling markers using
TUDCA or PBA (or genetically by the overexpression of glucose
response protein 78 Grp78), does not protect myotubes from fatty acid
(palmitate) induced alterations of insulin signaling [116]. This would
suggest that there may be tissue speciﬁc effects of chemical chap-
erone treatment or that there is dissociation between improvements in
ER stress and corresponding effects on insulin signaling in skeletal
muscle. This is an important consideration given the importance of
skeletal muscle in insulin-stimulated whole body glucose disposal.
10.4. Chemical chaperones in the clinic
From a clinical perspective, PBA has been approved for human use and
has been used in trials for multiple diseases [117,118] while TUDCA is
the taurine conjugate form of ursodeoxycholic acid (UDCA), used to treat
primary biliary cirrhosis [119,120] Given that both PBA and TUDCA have
been safely used in humans, the potential exists for testing these or
similar compounds in proof of principle trials for T2DM. To our
knowledge one such trial has taken place with some degree of success.
TUDCA treatment for four weeks (1750 mg/day) in obese, insulin
resistant human patients increased both hepatic and muscle insulin
sensitivity by 30% with no change in adipose tissue insulin sensitivity
[121]. This improvement in insulin sensitivity was associated withMOLECULAR METABOLISM 3 (2014) 781e793  2014 The Authors. Published by Elsevier GmbH. This is an open
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substrate (Tyr) and Akt (Ser473) levels). Interestingly, markers of ER
stress in muscle or adipose tissue did not change after treatment with
either TUDCA or placebo indicating that the improvement in whole body
insulin sensitivity was independent of improved ER stress in these
tissues [121]. It is plausible that ER stress was improved speciﬁcally in
the liver but this was unable to be determined due to the invasive nature
of such testing. Further, chronic, blinded placebo controlled trials will be
needed to decipher whether chemical chaperones targeting the ER
stress pathway is a bone ﬁde therapeutic for T2DM patients.
There is a gap in our understanding regarding the impact of chemical
chaperones on organelles other than the ER. For example, how the
chemical chaperones inﬂuence the mitochondria is largely unknown.
Future studies directed at examining mitochondrial speciﬁc chemical
chaperones may prove useful in identifying novel targets for metabolic
conditions.
11. IN SUMMARY
Diabetes and obesity are of a major public health concern. We have
summarized here proposed roles of Hsp72 in altering known pathways
to insulin resistance. Regardless of the method used to overexpress
Hsp72, heat treatment, genetic and pharmacological manipulation of
this protein results in improved measures of insulin sensitivity in both
high fat diet and genetic models of rodent obesity. Furthermore, these
improvements appear to be tightly linked with a reduction in JNK1
phosphorylation and/or an increase in oxidative capacity consequential
of improvements in mitochondrial homeostasis. Targeted manipulation
of Hsp72 with BGP-15 (or other modiﬁed hydroxylamine derivates),
GGA, as yet unidentiﬁed compounds, or simple heat treatment may have
clinical utility in treating metabolic disorders. Further studies are also
warranted to investigate the role of chemical chaperones as a potential
future pharmacological approach to combat metabolic diseases.
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